Eyenovia/EYEN

$2.15

8.59%
-
1D1W1MYTD1YMAX

About Eyenovia

Eyenovia, Inc. is a pre-commercial ophthalmic technology company. The Company is developing the Optejet delivery system both for use in combination with its own drug-device therapeutics and for out-licensing for use in combination with therapeutics for additional indications. Its product candidates include MicroLine (for presbyopia), MicroPine (for progressive myopia) and Mydcombi (for mydriasis). MicroLine is its microdosed version of pilocarpine, a well-understood ophthalmic medication that can dose-dependently induce miosis, or a contraction of the pupil. MicroPine is a topical treatment for progressive myopia, a back-of-the-eye disease. MicroPine program involves the development of a micro-formulation of atropine ophthalmic solution for reduction of myopia progression in children. Mydcombi is a fixed combination micro-formulation product candidate for mydriasis (eye dilation). Its fixed combination product candidate has been developed to facilitate efficient pupil dilation.

Ticker

EYEN

Sector

Tervishoid

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Tsontcho Ianchulev

Employees

41

Headquarters

New york, United States

Eyenovia Metrics

BasicAdvanced
$74.57M
Market cap
-
P/E ratio
-$0.67
EPS
1.66
Beta
-
Dividend rate

What the Analysts think about Eyenovia

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 3 analysts.
473.49% upside
High $15.00
Low $10.00
$2.15
Current price
$12.33
Average price target

Eyenovia Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-7.3M
17.74%
Profit margin
0%
-

Eyenovia Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 0%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.17
-$0.15
-$0.16
-$0.18
-
Expected
-$0.21
-$0.19
-$0.18
-$0.18
-$0.17
Surprise
-17.07%
-21.26%
-8.57%
0%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Eyenovia stock

Buy or sell Eyenovia stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing